Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Active Not RecruitingNCT01953588
What this trial is testing

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast Carcinoma+6 more
Alliance for Clinical Trials in Oncology 1,473
Not applicableStudy completedNCT01928186
What this trial is testing

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+7 more
University of Washington 28
Testing effectiveness (Phase 2)Ended earlyNCT01230970
What this trial is testing

Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Ipsen 2
Not applicableStudy completedNCT06006910
What this trial is testing

Electronic Medical Record-Based Nudge to Reduce SLNB

Who this might be right for
Breast CancerEstrogen-receptor-positive Breast Cancer
University of Pittsburgh Medical Center 7
Not applicableUnknownNCT01420185
What this trial is testing

Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28

Who this might be right for
Breast Cancer
NSABP Foundation Inc 1,300
Not applicableNot Yet RecruitingNCT06729099
What this trial is testing

Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients

Who this might be right for
Breast Cancer, Estrogen Receptor-Positive
Assiut University 128
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Not applicableStudy completedNCT00966043
What this trial is testing

Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes

Who this might be right for
Breast Neoplasms
Vlaamse Vereniging voor Obstetrie en Gynaecologie 158
Early research (Phase 1)Looking for participantsNCT05187832
What this trial is testing

AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Kind Pharmaceuticals LLC 61
Testing effectiveness (Phase 2)Study completedNCT00755885
What this trial is testing

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 77
Early research (Phase 1)Study completedNCT05551897
What this trial is testing

Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Who this might be right for
Healthy Subjects
AstraZeneca 14
Not applicableLooking for participantsNCT04476485
What this trial is testing

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Who this might be right for
Breast Cancer
Shengjing Hospital 1,000
Not applicableEnded earlyNCT05560685
What this trial is testing

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 10
Not applicableStudy completedNCT03886389
What this trial is testing

Breast Cancer Diet Intervention Study

Who this might be right for
Early-stage Breast CancerCarbohydrate EngorgementProliferation+2 more
Helse Stavanger HF 80
Early research (Phase 1)Study completedNCT01273168
What this trial is testing

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

Who this might be right for
Hormone Receptor-Positive BreastGynecologicDesmoid+1 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Not applicableStudy completedNCT01738152
What this trial is testing

Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health

Who this might be right for
Breast CancerEndometrial Cancer
Memorial Sloan Kettering Cancer Center 106
Not applicableEnded earlyNCT01346579
What this trial is testing

Biomarkers in Tissue Samples From Older Women With Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 505
Not applicableUnknownNCT03790813
What this trial is testing

Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 50
Next Page